Several randomized clinical trials have shown that the use of poly ADP ribose polymerase (PARP) inhibitors, such as olaparib (the OlympiAD trial) [30] or talazoparib (the EMBRACA trial) [31], has been associated with better progression-free survival (PFS) compared to single-agent palliative chemotherapy in patients with locally advanced or metastatic HER2-negative breast cancer with a pathogenic/likely pathogenic germline BRCA1/2 mutation. This evidence concerns the gene BRCA1 and breast carcinoma.